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Background: We retrospectively studied the impact of the introduction of new P2Y12 inhibitors (prasugrel,
ticagrelor) on platelet reactivity and clinical outcomes after Acute Coronary Syndrome (ACS) from a large single
center registry.
Methods: Consecutive patients admitted for ACS since 2007 and discharged on dual antiplatelet therapy were
enrolled. Biological response was assessed onemonth after discharge by PRI VASP and ADP-induced aggregation
(%ADP). Patients were classiﬁed according to PRI VASP as very low on-treatment platelet reactivity (VLTPR) (PRI
VASP ≤ 10%), low on-treatment platelet reactivity (LTPR) (PRI VASP ≤ 20%) and high on-treatment platelet
reactivity HTPR (PRI VASP N 50%). Ischemic and bleeding complications were reported.
Results: 1999 patients were analyzed, 605 before (July 2007–February 2010) and 1394 after introduction of new
P2Y12 blockers (February 2010–August 2013). After introduction, we reported a signiﬁcant lower PRI VASP
values (38% ± 0.53 vs. 42% ± 0.81 p = 0.001), %ADP aggregation (52% ± 0.4 vs. 54% ± 0.6 p = 0.03) and
HTPR incidence (22% versus 34% OR [95% CI]:0.65 [0.53–0.80]; p b 0.001). Conversely, incidence of VLTPR and
LTPR were signiﬁcantly higher after the introduction of new P2Y12 inhibitors: 6% versus 3% (OR [95% CI]: 2.0
[1.2–3.3]; p b 0.01) and 19% versus 8% (OR [95% CI]: 2.8 [2.0–3.9]; p b 0.001) respectively. Clinical follow-up
conﬁrmed biological ﬁndings with higher incidence of bleeding 10% versus 5% (OR [95% CI]: 2.1 [1.4–3.2]; p b 0.01)
and lower incidence of stent thrombosis 1.3% versus 3.3% (OR [95% CI]: 0.39 [0.20–0.73]; p b 0.01) with new
P2Y12 blockers.
Conclusion: The introduction of new P2Y12 inhibitors modiﬁed both platelet reactivity and clinical outcome of ACS
patients, with higher rate of hyper responders and bleedings, and lower rate of non responders and thrombotic
events.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Oral antiplatelet therapy including aspirin and P2Y12 inhibitors are
widely used with proven beneﬁt for the prevention of recurrent ische-
mic events after acute coronary syndrome (ACS) and current guidelines
recommend the use of dual antiplatelet therapy (DAPT) since CUREgie, CHU Timone, Marseille F-
.
nd Ltd. This is an open access article unresults in 2001 [1–6]. Clopidogrel has been considered as the gold stan-
dard therapy [6] before new P2Y12 blockers demonstrated their clinical
beneﬁt in large randomized controlled trials [7,8]. When ﬁrst introduced,
prasugrel had proved its superiority over clopidogrel in the TRITON
study; nevertheless its use was associated with an increased bleeding
risk [7]. ticagrelor, the latest P2Y12 receptor inhibitor commercialized in
2012, provided signiﬁcant reduction of mortality and prevention of
major adverse cardiac outcomes but with a signiﬁcant excess of major
bleedings compared to clopidogrel [8]. New P2Y12 blockers have greater
potency and faster onset than clopidogrel for which response is highly
variable [9]. Individual response to antiplatelet agents exists and clinical
relevance of platelet function testing has been demonstrated for ischemicder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1








Female gender (n, %) 411 (21%) 116 (19%) 295 (21%)
Age (years; m ± SD) 64.1 ± 12.5 64.6 ± 12.4 64.0 ± 12.5
BMI (kg/m2; mean ± SD) 26.8 ± 4.3 26.7 ± 4.3 26.9 ± 4.3
Hypertension (n, %) 1121 (56%) 364 (60%) 757 (54%) 0.02
Type II diabetes (n, %) 570 (29%) 174 (29%) 396 (28%)
Dyslipidemia (n, %) 1075 (54%) 338 (56%) 737 (53%)
Current smoker (n, %) 714 (36%) 233 (39%) 481 (35%)
Previous CAD (n, %) 616 (31%) 129 (21%) 487 (35%) 0.01
Beta blocker (n, %) 1362 (68%) 446 (74%) 916 (66%) 0.01
ACE-inhibitors (n, %) 1334 (67%) 439 (73%) 895 (64%) 0.01
New P2Y12 inhibitor (n, %) 633 (32%) 0 633 (45%)
STEMI (n, %) 585 (29%) 191 (32%) 394 (28%)
Number stent (m ± SD) 1.3 ± 0.6 1.2 ± 0.6 1.3 ± 0.7
DES (n, %) 1186 (59%) 266 (44%) 920 (66%) 0.001
Stent length (m ± SD) 20.2 ± 12.2 18.2 ± 9.7 21.0 ± 13.1 0.01
Gp 2b3a inhibitor (n, %) 636 (32%) 229 (38%) 407 (29%) 0.01
EF (%; m ± SD) 54.9 ± 8.4 54.4 ± 8.5 55.2 ± 8.3 0.04
Insulin (mUI/l; m ± SD) 13.6 ± 16.1 13.0 ± 12.0 13.8 ± 17.4
CRP (mg/l; m ± SD) 5.5 ± 14,4 5.3 ± 17.0 5.6 ± 13.1
Triglyceride (G/L; m ± SD) 1.3 ± 0.8 1.2 ± 0.7 1.3 ± 0.9 0.03
Cholesterol (G/L; m ± SD) 1.5 ± 0.4 1.5 ± 0.4 1.5 ± 0.4
HDL (G/L; m ± SD) 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.01
LDL (G/L; m ± SD) 0.8 ± 0.3 0.9 ± 0.3 0.8 ± 0.3 0.01
HbA1c (%; m ± SD) 6.3 ± 1.0 6.2 ± 1.0 6.3 ± 1.1
M: mean; SD: standard deviation; STEMI: ST elevation myocardial infarction; NSTEMI:
non ST elevation myocardial infarction; EF: ejection fraction; CAD: coronary artery dis-
ease; HDL: high density lipoprotein; LDL: low density lipoprotein; HbA1C: glycosylated
hemoglobin; ACE = angiotensin-converting enzyme; GP: platelet glycoprotein; DES:
drug eluting stent.
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to daily practice is important for newdrug evaluation andmodiﬁcation of
ACS landscape after therapeutic evolution shouldbe assessed continuous-
ly after introduction of new drugs' effectiveness. Therefore, the present
study aimed to assess in a large registry the evolution of platelet reactivity
and clinical outcomes after ACS before and after introduction of new
P2Y12 blockers.
2. Methods
All consecutive patients admitted in our institution for Non ST Eleva-
tion ACS (NSTE ACS) or ST Elevation Myocardial Infarction (STEMI),
between July 2007 and August 2013, were eligible if they had undergone
successful percutaneous coronary intervention (PCI). Patients were
treated with a loading dose of antiplatelet therapy before PCI (i.e.
clopidogrel 600 mg, prasugrel 60 mg or ticagrelor 180 mg). All patients
were treated at discharge with a P2Y12 inhibitor in association with
aspirin 75 mg for one year. P2Y12 blockers used were clopidogrel
75 mg/d, clopidogrel 150 mg/d, prasugrel 10 mg/d or ticagrelor 90 mg
twice a day. Two periods were deﬁned before and after introduction of
new P2Y12 (prasugrel was the ﬁrst drug to be introduced in February
2010). Clinical follow-up was performed for all patients at one month
and six months. Biological response was assessed at one month
clinical follow-up by % platelet reactivity index vasodilator-stimulated
phosphoprotein (PRI VASP) and ADP-induced aggregation (%ADP).
Based on PRI VASP, patients were classiﬁed as: very low on-treatment
platelet reactivity (VLTPR = PRI VASP ≤ 10%) [13], low on-treatment
platelet reactivity (LTPR = PRI VASP ≤ 20%) [14], high on-treatment
platelet reactivity (HTPR = PRI VASP N 50%) [15] or normoresponders
(20% b PRI VASP ≥ 50%). Adherence was systematically assessed during
the two follow-up visits. The exclusion criteria were a history of bleeding
diathesis, prior stroke or transient ischemic attack for prasugrel therapy,
platelet count b100G/L. The ethics committee of our institution approved
the study protocol, and patients gave written informed consent for
participation. Blood was sent immediately to the hemostasis laboratory
to determine the VASP phosphorylation state ofwhole blood.Weused a
standardized ﬂow cytometric assay [Platelet VASP®; Diagnostica Stago
(Biocytex), Asnières, France], which is an adaptation of the method of
Schwarz et al. previously described [16]. PRI VASP was calculated
from the median ﬂuorescence intensity (MFI) of samples incubated
with PGE1 or PGE1 and ADP according to the formula: PRI VASP =
[MFI(PGE1) − MFI(PGE1 + ADP) / MFIPGE1] × 100. The platelets were
stimulated with ADP (10 μmol/L), and aggregation was assessed with a
PAP4 aggregometer (Biodata, Wellcome, Paris, France). Aggregation is
expressed as the percentage of change in light transmittance from base-
line, with platelet-poor plasma as the reference. In the present study,
we report the data on the maximum intensity of 10 μM/L ADP-induced
platelet aggregation.
The clinical endpointwas the occurrence of bleeding events according
to the BleedingAcademicResearchConsensus deﬁnitionswith type 1, 2, 3
or 5 (type 4 was not expected while no patient had planned coronary
artery bypass grafting) [17] and ischemic complications (deﬁnite or
possible stent thrombosis using the Academic Research Consortium
deﬁnition) [18] during the ﬁrst six months. Radial access is widely
used in our center and access-site bleedings less dependent of platelet
inhibition; we collected only the non-access site bleeding complications.
The primary endpoints of the present study were deﬁned as:
– Evolution of platelet reactivity status before and after new P2Y12
inhibitors introduction.
– Bleeding complications and stent thrombosis before and after new
P2Y12 inhibitors introduction.
Statistical analysis was performed using PASW Statistics version 17.0.
Continuous variables were reported as means and standard deviation or
as medians and range (according to their distribution), and categorical
variables were reported as count and percentages. Standard 2-sidedtests were used to compare continuous characteristics (Student t or
Mann–WhitneyU tests) or categorical characteristics (chi-square or Fish-
er exact tests) among patient groups. Odds ratios (OR) were estimated
with a 95% conﬁdence interval. For all tests, statistical signiﬁcance was
deﬁned as p b 0.05.
3. Results
1999 consecutive patients undergoing PCI with coronary stenting for
ACS between 2007 and 2013 were prospectively included in our registry.
Prasugrel was used for the ﬁrst time in February 2010 and ticagrelor was
introduced in February 2013. We included 605 patients in the “before”
cohort and 1394 in the “after” cohort. Characteristics of the two cohorts
are reported and compared in Table 1. We observed signiﬁcant differ-
ences concerning use of GPIIbIIIa inhibitors (38% before vs. 30% after
p = 0.01) and LDL-Chol level was lower at one month in the “after”
cohort (p = 0.02). Before the introduction of new P2Y12 agents, 117
patients (19%) were on clopidogrel 75 mg and 488 (81%) on clopidogrel
150 mg. After, we observed 295 patients (21%) on clopidogrel 75 mg,
466 (33%) on clopidogrel 150 mg, 566 (41%) on prasugrel, and 67 (5%)
on ticagrelor. Drug eluting stents (DES) were used in 66% of the after co-
hort patients (460 on clopidogrel, 423 on prasugrel and 37 on ticagrelor).
No difference concerning anticoagulation protocol was reported in the
after cohort compared with before. We observed a signiﬁcant evolution
of platelet reactivity with signiﬁcantly lower %PRI VASP and %ADP
aggregation after than before introduction: 38% ± 0.53 vs. 42% ± 0.81,
p = 0.001 and 52% ± 0.4 vs. 54% ± 0.6, p = 0.03 respectively (Fig. 1A
and B). Incidence of VLTPR and LTPR were signiﬁcantly higher after
than before: 6% (n = 84) vs. 3% (n = 19) (OR [95% CI]: 2 [1.2–3.3];
p b 0.01) and 19% (n = 270) vs. 8% (n = 48) (OR [95% CI]: 2.8
[2.0–3.9]; p b 0.001) respectively. Conversely, incidence of HTPR was
higher before than after: 34% (n = 204) vs. 22% (n = 345) (OR [95%
CI]: 1.5 [1.3–1.9]; p b 0.001) (Fig. 2).We observed 9% of bleeding compli-
cations (n = 170) in the global cohort, corresponding to 5% (n = 30) of
bleeding complications before versus 10% (n = 140) after (OR [95%
Fig. 1.A and 1B: Comparison of platelet inhibition before and after introduction of newP2Y12agents.We observed a signiﬁcant evolution of platelet reactivitywith signiﬁcantly lower %PRI
VASP and %ADP aggregation after than before introduction of new P2Y12 blockers. PRI VASP (Platelet Reactivity Index Vasodilator-Stimulated Phosphoprotein).
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ed 24 BARC 1 (80%), 4 BARC 2 (13%) and 2 BARC 3 (7%) versus 100 BARC
1 (77%), 22 BARC 2 (17%), and 8 BARC 3 (6%) in the after cohort.
Conversely, incidence of stent thrombosis was higher before than
after introduction of new P2Y12 blockers: 3.3% (n = 20) vs. 1.3% (n =
18) (OR [95% CI]: 2.6 [1.4–4.9]; p b 0.01) (Fig. 3).
Patients in the after cohort suffering from ST corresponded to 10 on
clopidogrel, 7 on prasugrel and one on ticagrelor. In 9 patients DES
were used. Bleeding complications were reported in 44 patients on
clopidogrel, 82 patients on prasugrel and 14 patients on ticagrelor.
In the overall population, we observed signiﬁcantly lowers levels of
PRI VASP (27.6% ± 1.3 vs.40.1% ± 0.5, p b 0.001) and %ADP (41.7% ±
1.1 vs. 53.6 ± 0.4, p b 0.001) in patients with bleeding complications in
comparisonwithpatientswithout bleeding complications. This difference
remains signiﬁcant in the two cohorts before and after (p b 0.01 for both).
Also, we conﬁrmed that VLTPR (OR [95% CI]: 4.1 [2.6–6.5]; p b 0.001)
and LTPR (OR [95% CI]: 4.5 [2.9–5.6]; p b 0.001) are strong predictors of
bleeding complications.Fig. 2. Platelet reactivity status evolution since introduction of new P2Y12 inhibitors. Inci-
dence of VLTPR and LTPRwere signiﬁcantly higher after than before, inversely HTPR is less
frequent after. VLTPR (Very Low on Treatment Platelet Reactivity) LTPR (Low on Treat-
ment Platelet Reactivity). HTPR (High on Treatment Platelet Reactivity).4. Discussion
The key observation of the present study is a marked shift in clinical
and biological pattern of ACS patients since the introduction of newer
P2Y12 blockers. These agents provide a more potent platelet inhibition,
and decrease resistance status and ischemic complications but are asso-
ciated with more bleeding events and hyperresponse.
Prasugrel is a thienopyridine, pro-drug converted into an irreversible
P2Y12 receptor inhibitor, similar to the one originated from clopidogrel,
but which different metabolisms lead to higher and faster platelet inhibi-
tion in patients with coronary artery disease [19]. Ticagrelor is an oral,
direct, and reversible P2Y12 inhibitor, which has a shorter half-life and
requires twice-daily intakes [20]. Both two drugs have a rapid onset of
action and are less affected by CYP2C19 polymorphisms. Both TRITON
and PLATO trials proved the superiority of new P2Y12 blockers on
clopidogrel concerning ischemic endpoints (death,myocardial infarction,
stroke, stent thrombosis and urgent revascularization) [7,8]. Neverthe-
less, this high efﬁcacy is counterbalanced by an excess of bleedingFig. 3. Stent thrombosis and bleeding complication comparison before and after introduc-
tion of new P2Y12 inhibitors. Stent thrombosis signiﬁcantly decreases and conversely
bleeding complications are more frequent during the “after” period.
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observations about all-comer ACS patients are relevant. Stent thrombosis
is the major complication feared by interventional cardiologists after
stent implantation and evidence has accumulated that the persistence
of thrombotic events after PCI might be related to speciﬁc limitations of
clopidogrel [22]. Following numerous studies, it had been conﬁrmed
that insufﬁcient P2Y12 receptor inhibition (HTPR) is associated with a
higher risk for thrombotic events after PCI [23–25]. Introduction of a
loading dose and new antiplatelet agents signiﬁcantly participated in
the decline of stent thrombosis. New DES are also implicated in the
literature on reduction of ischemic complications [26]. In our cohort the
few number of ST does not allow a comparison between DES and bare
metal stent concerning ST (9 patients suffering from ST were implanted
with DES). Accordingly, in our registry we observed an important de-
crease in the %HTPR patients and the occurrence of stent thrombosis
since the introduction of new P2Y12 blockers. Integrating these ﬁndings,
clinicians should be concerned about ischemic events but also bleeding
complications [27]. Some trials have shown that excessive platelet inhibi-
tion on clopidogrel is a predictor of major bleeding events [28–30]. More
recently, VLTPR was found to be a strong and independent biological
predictor of bleeding complications on thienopyridines, [13]. We ob-
served that the introduction of new P2Y12 leads to a signiﬁcant increase
in %VLTPR and %LTPR patients associated with 10% bleeding risk in actual
ACS patients. In our cohort the majority of bleeding events are BARC1
nuisance bleedings (77%). However, these bleedings have signiﬁcant
clinical relevance while they might lead to treatment discontinuation
[31,32]. Also, comparison of the new P2Y12 blockers is still an unad-
dressed question for clinical outcomes and no properly sized randomized
clinical trial will be performed to provide a deﬁnite answer. A recent
biological study from our group showed that ticagrelor is associated
with higher platelet inhibition and higher incidence of ‘hyper response’
than prasugrel one month after ACS [33]. Three meta-analysis compared
prasugrel to ticagrelor failing to prove superiority on mortality [34–36].
Comparison of prasugrel versus ticagrelor foundno signiﬁcant differences
in death, MI and stroke. Prasugrel, when compared to ticagrelor, was
associatedwith adecrease in stent thrombosis.Major bleeding not related
to bypass surgery was similar between the two agents.
Also, platelet testing might play a role in stratifying ischemic and
bleeding risk and evaluating ischemic versus bleeding risk but not guiding
antiplatelet agent choice. Randomized studies assessing a personalized
therapy based on platelet testing did not prove the efﬁciency of this
strategy [23,37,38]. These studies included mainly patients with stable
coronary artery disease and did not focus on ACS patients undergoing
PCI. Actually, platelet function testing should be used to try tailoring
therapy and to reach an optimal level of platelet inhibition, protecting
patients against thrombosiswithout reaching an excessive level of inhibi-
tion that would predispose patients to bleeding, aiming for a ‘therapeutic
window’. Also, new P2Y12 agents could possibly be avoided in patients
with high bleeding risk, such as those with previous stroke, non diabetic,
advanced age, severe renal failure or low weight where clopidogrel will
continue to maintain a major role, deﬁning a tailored approach based
on patient's characteristics. Platelet testing can help clinicians stratifying
ischemic versus bleeding risk and should be included in global risk
estimation, mostly guided by clinical risk evaluation. Association of
aspirin and P2Y12 blocker is recommended during one year after ACS
[1,2], covering a ﬁrst high thrombotic phase, however long term treat-
ment exposes patients to bleeding risk, and new strategies for DAPT are
required. The ongoing GLOBAL LEARDERS trial (NCT 01813435) will
test, in a randomized study concerning all-comers stent procedures, a
new strategy with 1 month DAPT followed by 23 month ticagrelor
alone versus 12 month DAPT followed by aspirin alone indeﬁnitely on
safety/efﬁcacy balance. Few studies evaluating a switching therapy
based on the platelet reactivity showed reach objectives only concerning
biological platelet inhibition [39–41].With newP2Y12 blockers achieving
a signiﬁcant reduction in stent thrombosis occurrence, actual challenges
are the reduction of long term bleeding events. This evaluation shouldtake place in a “dynamic therapy”, switching a high potent treatment
once passed the ﬁrst ischemic phase, to clopidogrel which could reduce
bleeding events. Clinical impact of these ﬁndings warrants further
investigation to recommend P2Y12 inhibitor switching according to
individual risk.
5. Study limitations
The intrinsic limitations of this study result from the observational
characteristic of a registry and its retrospective analysis. Also,we included
few patients on ticagrelor, due to the recent commercialization of this
drug in our country.
6. Conclusion
Introduction of new P2Y12 inhibitors leads to a modiﬁcation on ACS
patient's proﬁle, increasing hyper responders versus low responders.
Meanwhile, the same trend was observed for clinical outcomes with
less stent thrombosis and more bleeding. This evolution modiﬁes
targets during long term management of ACS patients on DAPT.
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